This review describes the impact of nonmedical switching of biologic therapies on US patients and providers, with a focus on switching to in-class alternatives.
Mark Lebwohl, MD
Advertisement
Articles by Mark Lebwohl, MD
The panel details the clinical and economic burden when patients switch between agents in plaque psoriasis.
Bhavesh Shah, PharmD, and Robert Groves, MD, discuss the priorities payers should be taking into account when managing psoriasis treatment.
Advertisement
Latest Updated Articles
Impact of Switching Agents in Plaque PsoriasisPublished: December 1st 2021 | Updated:
- Perspectives on Nonmedical Switching and the COVID-19 Pandemic: A Narrative Review
Published: September 26th 2022 | Updated:
Utilization Management in PsoriasisPublished: December 1st 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
Near Low–Income Medicare Beneficiaries Face More Affordability Problems Than Other Income Groups
3
Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting
4
Childhood Insurance Dynamics Predict Medicaid Cuts Will Widen Gaps
5
